Market Overview

Top 4 NYSE Stocks In The Biotechnology Industry With The Highest Revenue Estimates

Related CRL
Positives In Charles River Labs 'Largely Reflected In Industry-High Valuation'
Mid-Morning Market Update: Markets Open Higher; Time Warner Posts Mixed Q4 Results
Best Near-Term Price Gains Ahead For: Medical Services Stocks (Seeking Alpha)
Related EBS
Emergent BioSolutions To Implement $50 Million Share Buyback Program
10 Biggest Mid-Day Losers For Wednesday

Below are the top biotechnology stocks on the NYSE in terms of revenue estimate for the current year.

Analysts expect Charles River Laboratories International (NYSE: CRL) to post revenue of $1.14 billion for the year ending December, 2012. Charles River Laboratories' trailing-twelve-month ROE is 17.83%.

Emergent BioSolutions (NYSE: EBS) is expected to report revenue of $286.38 million for the year ending December, 2012. Emergent BioSolutions' PEG ratio is 0.72.

Cambrex (NYSE: CBM) is likely to post revenue of $274.60 million in the year ending December, 2012. Cambrex's trailing-twelve-month operating margin is 12.83%.

ShangPharma (NYSE: SHP) may report revenue of $132.94 million in the year ending December, 2012. ShangPharma had $34.74 million in total cash for the recent quarter.

Posted-In: Biotechnology Industry Highest Revenue Estimates NYSETrading Ideas


Related Articles (CBM + CRL)

View Comments and Join the Discussion!